Change in Director / Key Managerial Personnel

  • Nature of change: Appointment of Dr. Shyam Ramakrishnan as Chief Scientific Officer, forming part of the Senior Management of the Company.
  • Name and details: Dr. Shyam Ramakrishnan. A DIN number is not provided in the disclosure.
  • Effective date and tenure: The appointment is effective from July 1, 2026. The term of appointment is a full-time contract.
  • Profile and qualifications: Dr. Ramakrishnan holds a PhD in Biological Chemistry & Genetics from the University of Texas. He has completed postdoctoral fellowships at Harvard Medical School and Hoffmann-La Roche. He brings over 25 years of experience across nutrition, dietary supplements, beauty, personal care, and functional foods. His expertise includes translational science, clinical research, bioinformatics, and innovation platform development. He has experience leading large cross-functional teams across the US, India, Southeast Asia, and other international markets.
  • Previous roles: He has held key leadership roles with organizations like Hill's Pet Nutrition, The Himalaya Drug Company, ITC Ltd., and Amway (in the United States, Southeast Asia & Brazil).
  • Confirmation of eligibility: The disclosure states the appointment was based on the recommendation of the Nomination and Remuneration Committee and approved by the Board of Directors, implying compliance with governance norms. A specific declaration of non-disqualification is not included.
  • Relationship with other directors: The annexure states "Not applicable" for the disclosure of relationships between directors, indicating he has no disclosed relationships with other directors or promoters.
  • Previous KMP: The disclosure does not mention who held the position of Chief Scientific Officer earlier or the nature of their exit, so it cannot be determined if the succession was planned or interim.

Key Financial or Operational Approvals

This section does not apply to the provided data. The disclosure is solely regarding a management appointment and does not contain any information on financial results, fundraising, acquisitions, or other operational approvals.

Strategic or Business Context

This section does not apply to the provided data. The disclosure does not contain any commentary on business outlook, risks, demand trends, expansion plans, or capital allocation strategy.

Any Other Material Information

  • Regulatory compliance: The disclosure is made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.
  • Company contact: The filing is signed by Nandish P. Joshi, Company Secretary & Compliance Officer.